{"id":99799,"date":"2023-06-09T00:00:00","date_gmt":"2023-06-09T00:00:00","guid":{"rendered":"https:\/\/medgoo.com\/index.php\/2023\/06\/09\/asco-folfox-noninferior-to-chemoradiotherapy-for-overall-survival-in-rectal-cancer\/"},"modified":"2023-06-12T17:16:12","modified_gmt":"2023-06-12T17:16:12","slug":"asco-folfox-noninferior-to-chemoradiotherapy-for-overall-survival-in-rectal-cancer","status":"publish","type":"post","link":"https:\/\/medgoo.com\/index.php\/2023\/06\/09\/asco-folfox-noninferior-to-chemoradiotherapy-for-overall-survival-in-rectal-cancer\/","title":{"rendered":"ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer"},"content":{"rendered":"<h3>\n<p>Findings seen in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery<\/p>\n<\/h3>\n<p><b>By Elana Gotkine HealthDay Reporter<\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, June 9, 2023 (HealthDay News) &#8212; Neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is noninferior to preoperative chemoradiotherapy with respect to overall survival for patients with locally advanced rectal cancer who are eligible for sphincter-sparing surgery, according to a study published online June 4 in the <em>New England Journal of Medicine<\/em> to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.<\/p>\n<p>Deborah Schrag, M.D., M.P.H., from the Memorial Sloan Kettering Cancer Center in New York, and colleagues conducted a multicenter noninferiority trial of neoadjuvant FOLFOX as compared to chemoradiotherapy among patients with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery. Disease-free survival was assessed as the primary end point.<\/p>\n<p>Data were analyzed for 1,128 patients who started treatment: 585 and 543 in the FOLFOX and chemoradiotherapy groups, respectively. The researchers found that FOLFOX was noninferior to chemoradiotherapy for disease-free survival at a median follow-up of 58 months (hazard ratio for recurrence of death, 0.92; 90.2 percent confidence interval, 0.74 to 1.14; P = 0.005 for noninferiority). Five-year disease-free survival was 80.8 and 78.6 percent in the FOLFOX and chemoradiotherapy groups, respectively. With respect to overall survival and local recurrence, the groups were similar.<\/p>\n<p>&#8220;The findings in this trial have extended the therapeutic options by showing the noninferiority of neoadjuvant FOLFOX with selective use of chemoradiotherapy to the prevailing standard of neoadjuvant chemoradiotherapy,&#8221; the authors write.<\/p>\n<p><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2303269\" target=\"_blank\" rel=\"noopener\">Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n<p><a href=\"https:\/\/conferences.asco.org\/am\/attend\" target=\"_blank\" rel=\"noopener\">More Information<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2023 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings seen in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery<\/p>\n","protected":false},"author":6,"featured_media":99880,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[11],"class_list":["post-99799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"_links":{"self":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/99799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/comments?post=99799"}],"version-history":[{"count":1,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/99799\/revisions"}],"predecessor-version":[{"id":99879,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/posts\/99799\/revisions\/99879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media\/99880"}],"wp:attachment":[{"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/media?parent=99799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/categories?post=99799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medgoo.com\/index.php\/wp-json\/wp\/v2\/tags?post=99799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}